Key result
Cardiac sympathetic nerve imaging using 123I-MIBG scintigraphy is a useful tool for assessing prognosis and predicting sudden cardiac death in patients with heart failure.
Why the study?
Does 123I-MIBG scintigraphy predict sudden cardiac death in patients with heart failure?
Does 123I-MIBG scintigraphy predict sudden cardiac death in patients with heart failure?
Cardiac sympathetic nerve imaging using 123I-MIBG scintigraphy is a useful tool for risk stratification and predicting sudden cardiac death in patients with heart failure, potentially guiding ICD placement better than LVEF alone.
May aid HF risk stratification; hypothesis-generating and requires prospective validation before guiding therapy.
The autonomic nervous system plays an important role in the human heart. Activation of the cardiac sympathetic nervous system is a cardinal pathophysiological abnormality associated with the failing human heart. Myocardial imaging using (123)I-metaiodobenzylguanidine (MIBG), an analog of norepinephrine, can be used to investigate the activity of norepinephrine, the predominant neurotransmitter of the sympathetic nervous system. Many clinical trials have demonstrated that (123)I-MIBG scintigraphic parameters predict cardiac adverse events, especially sudden cardiac death, in patients with heart failure. In this review, we summarize results from published studies that have focused on the use of cardiac sympathetic nerve imaging using (123)I-MIBG scintigraphy for risk stratification of sudden cardiac death in patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Kasama et al. (2016) conducted a review in Heart failure. 123I-MIBG scintigraphy was evaluated. Cardiac sympathetic nerve imaging using 123I-MIBG scintigraphy is a useful tool for assessing prognosis and predicting sudden cardiac death in patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: